Key Points
- CFO Oluyemi Okupe sold 9,070 shares on Jan. 5 at $33.79 for $306,475, leaving him with 91,617 shares; this is part of multiple recent insider sales since October totaling over $2.6 million.
- Hims & Hers' board authorized a $250 million share repurchase (up to ~3% of stock) on Nov. 17, while the company reported revenue of $598.98M (up 49.2% YoY) but missed quarterly EPS at $0.06 versus $0.09, and trades at a high P/E of 65.65.
Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 9,070 shares of the stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $33.79, for a total transaction of $306,475.30. Following the completion of the sale, the chief financial officer directly owned 91,617 shares in the company, valued at approximately $3,095,738.43. The trade was a 9.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Oluyemi Okupe also recently made the following trade(s):
- On Monday, December 22nd, Oluyemi Okupe sold 23,090 shares of Hims & Hers Health stock. The stock was sold at an average price of $35.72, for a total transaction of $824,774.80.
- On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.
- On Monday, November 17th, Oluyemi Okupe sold 23,187 shares of Hims & Hers Health stock. The shares were sold at an average price of $36.81, for a total transaction of $853,513.47.
- On Friday, October 17th, Oluyemi Okupe sold 11,592 shares of Hims & Hers Health stock. The stock was sold at an average price of $57.13, for a total transaction of $662,250.96.
Hims & Hers Health Price Performance
HIMS stock opened at $35.45 on Thursday. Hims & Hers Health, Inc. has a 1 year low of $23.97 and a 1 year high of $72.98. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The stock's 50 day moving average price is $37.36 and its 200 day moving average price is $46.35. The firm has a market cap of $8.07 billion, a P/E ratio of 65.65, a PEG ratio of 5.74 and a beta of 2.37.
Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The company had revenue of $598.98 million for the quarter, compared to analysts' expectations of $578.99 million. During the same period in the previous year, the business posted $0.32 EPS. The business's quarterly revenue was up 49.2% on a year-over-year basis. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.
Hims & Hers Health declared that its board has initiated a share buyback plan on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's management believes its shares are undervalued.
Institutional Trading of Hims & Hers Health
A number of institutional investors and hedge funds have recently made changes to their positions in HIMS. Virtus Advisers LLC acquired a new position in Hims & Hers Health in the second quarter valued at $26,000. Quent Capital LLC acquired a new stake in Hims & Hers Health during the third quarter worth about $28,000. Binnacle Investments Inc purchased a new position in shares of Hims & Hers Health in the 3rd quarter worth about $28,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $29,000. Finally, Bessemer Group Inc. lifted its stake in shares of Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of research firms have recently weighed in on HIMS. KeyCorp began coverage on shares of Hims & Hers Health in a research report on Tuesday, October 21st. They issued a "sector weight" rating for the company. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research note on Monday. Wall Street Zen lowered Hims & Hers Health from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. BTIG Research restated a "buy" rating and set a $85.00 price objective on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, UBS Group set a $32.00 target price on Hims & Hers Health in a research note on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of "Hold" and a consensus target price of $45.50.
Read Our Latest Report on HIMS
Hims & Hers Health Company Profile
(
Get Free Report)
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.
The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
